Daewoong Pharmaceutical said its poster session on phase 1 clinical trial of DWP16001, a diabetes treatment, attracted the attention of participants attending the 2019 European Association for the Study of Diabetes.
|Daewoong headquarters in Samsung-dong, southern Seoul.|
The drug inhibits Sodium-glucose co-transporter-2 (SGLT-2) for type 2 diabetic patients. SGLT-2 inhibitor drugs selectively inhibit SGLT-2, a transporter that resorbs glucose in the kidneys to prevent glucose from being reabsorbed in the body and release it into the urine to regulate blood glucose.
In phase 1 clinical trial presented during the conference, DWP16001 showed excellent urine glucose secretion at 1/100 dose compared to other SGLT-2 inhibitor drugs. Also, the daily urine output of the treatment group was 50g after 15 days of repeated treatment, whereas the daily urine output of the control group was 40g.
The company, which plans to launch the drug in the domestic market by 2023, is conducting phase 2 clinical trials to evaluate its efficacy and safety at 40 local medical institutions, including Seoul National University Hospital.
“The poster session confirmed the global market's high interest in the development of DWP 16001,” Daewoong Pharmaceutical CEO Jeon Seng-ho said. “We will accelerate our R&D to make DWP16001 the best new drug in the SGLT-2 inhibitor family.”
<© Korea Biomedical Review, All rights reserved.>